Neuren Pharmaceuticals, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: $1.3B

Website

Clinical Trials

Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC

Phase 2

Completed

Conditions: Brain Injuries

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2011-06-06

Last Posted Date: 2018-02-05

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 261

Registration Number: NCT01366820

Locations: 🇺🇸
Arrowhead Regional Medical Center, Colton, California, United States
🇺🇸
University of California, Davis Medical Center, Sacramento, California, United States
🇺🇸
The Queen's Medical Center, Honolulu, Hawaii, United States

and more 3 locations

Safety Study of NNZ-2566 in Healthy Female Subjects

Phase 1

Completed

Conditions: Brain Injuries, Traumatic

Interventions: Drug: Placebo
Drug: NNZ-2566

First Posted Date: 2009-08-19

Last Posted Date: 2014-10-07

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 39

Registration Number: NCT00961779

Locations: 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia

Study of NNZ-2566 in Patients With Traumatic Brain Injury

Phase 2

Completed

Conditions: Brain Injuries

Interventions: Drug: NNZ-2566
Drug: Placebo

First Posted Date: 2008-12-10

Last Posted Date: 2018-02-05

Lead Sponsor: Neuren Pharmaceuticals Limited

Target Recruit Count: 261

Registration Number: NCT00805818

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
University of Miami, Lois Pope Life Center, Miami, Florida, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy